Pfizer‘s CEO signed on to an trade letter in help of the Meals and Drug Administration’s authority to manage medication after a federal decide in Texas suspended the company’s approval of the abortion capsule mifepristone. 

Albert Bourla was among the many greater than 200 pharmaceutical firm executives who signed the letter after U.S. Choose Matthew Kacsmaryk’s controversial ruling on Friday. 

The executives stated the choice “ignores a long time of scientific proof and authorized precedent.” Additionally they raised issues that the ruling will “set a precedent” for diminishing the FDA’s authority over drug approvals, which might create uncertainty for your entire trade. 

“If courts can overturn drug approvals with out regard for science or proof, or for the complexity required to totally vet the protection and efficacy of recent medication, any medication is in danger for a similar final result as mifepristone,” the executives stated within the letter. 

Kacsmaryk sided with an antiabortion group, arguing that the FDA rushed its approval course of and violated federal requirements. 

“The Court docket doesn’t second-guess FDA’s decision-making frivolously,” Kacsmaryk wrote in his determination. “However right here, FDA acquiesced on its legit security issues — in violation of its statutory responsibility — based mostly on plainly unsound reasoning and research that didn’t help its conclusions.”

Pfizer is the primary main pharmaceutical firm to publicly react to the ruling. Moderna and Johnson & Johnson didn’t instantly reply to a request for remark.

— CNBC’s Meg Tirrell and Spencer Kimball contributed to this report.